Completed OBSERVATIONAL NCT07151820
A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients
Association of Adverse Events in the Real World With Treatment Adjustments, and Burden of AEs in Patients With Chronic Myeloid Leukemia
Sponsor: Novartis Pharmaceuticals
Conditions
Leukemia, Chronic Myeloid
Updated 1 time since 2025 Last updated: Aug 25, 2025 Started: Apr 8, 2024 Primary completion: Oct 22, 2024 Completion: Oct 22, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This observational or N/A phase trial investigates Leukemia, Chronic Myeloid and is currently completed. Novartis Pharmaceuticals leads this study, which shows 1 recorded version since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Completed
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Novartis Pharmaceuticals
Data source: Novartis
For direct contact, visit the study record on ClinicalTrials.gov .